Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 0.68 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858581 | 0.89 | OPRM1 (0.76) | OPRM1OPRL1KMT2AMEN1MAPT | |
| Citric Acid SCHEMBL4858710 | 0.87 | OPRM1 (0.50) | OPRM1OPRL1KMT2AMEN1MAPT | |
| Citric Acid SCHEMBL4851146 | 0.85 | OPRL1 (0.57) | OPRM1OPRL1KMT2AMEN1MAPT | |
| Citric Acid SCHEMBL4858613 | 0.83 | OPRL1 (0.60) | OPRM1OPRL1KMT2AMEN1MAPT | |
| SCHEMBL4854835 | 0.81 | OPRM1 (1.00) | OPRM1OPRL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4858702 | 0.81 | OPRM1 (0.52) | OPRM1OPRL1KMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL4855916 | 0.80 | OPRM1 (1.00) | OPRM1OPRL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4858591 | 0.74 | OPRL1 (0.53) | OPRM1OPRL1KMT2AMEN1MAPT | |
| SCHEMBL5339483 | 0.74 | OPRL1 (0.48) | OPRM1OPRL1 | |
| SCHEMBL4849167 | 0.73 | OPRL1 (0.68) | OPRM1OPRL1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348354-B2 | Cyclohexylurea compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | GRUENENTHAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | OPRL1, OPRM1, OGFRL1 | OPRM1 2/4885MEN1 4861/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.